Key result
Predischarge sotagliflozin significantly reduces CV death and heart failure events through 90 days in diabetes.
Why the study?
Does sotagliflozin started before discharge reduce cardiovascular deaths and heart failure events in patients with type 2 diabetes hospitalized for worsening heart failure?
Does sotagliflozin started before discharge reduce cardiovascular deaths and heart failure events in patients with type 2 diabetes hospitalized for worsening heart failure?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
““Hospital readmissions are burdensome, time-consuming and costly. The results emphasize the importance of beginning SGLT inhibition before discharge.””
Initiating sotagliflozin prior to hospital discharge in patients with type 2 diabetes and worsening heart failure significantly reduces early cardiovascular mortality and heart failure events.
Starting sotagliflozin before discharge in patients with type 2 diabetes hospitalized for WHF significantly decreased cardiovascular deaths and HF events through 30 and 90 days after discharge, emphasizing the importance of beginning sodium glucose cotransporter treatment before discharge.
No takes yet. Share an insight, caveat, or question.
Pitt et al. (2023) studied this question. Starting sotagliflozin before discharge significantly decreased cardiovascular deaths and heart failure events through 30 and 90 days in hospitalized type 2 diabetes patients.
Synapse has enriched 10 related papers. Consider them for comparative context: